Pricing, Pediatrics, Pot: 21st Century Cures Amendments
Committee members didn’t even vote on any amendments besides the manager’s package, but proposals floated and withdrawn offer glimpse at potential fights to come.
You may also be interested in...
Approaches for HHS to become involved in drug price negotiations between Medicare Part D plan sponsors and manufacturers were outlined by HHS Assistant Secretary for Planning and Evaluation Richard Frank at a policy conference, although current law would need to be revised to allow it.
FDA requests enough pediatric rare disease priority review voucher user fees to fund three redemptions in fiscal year 2016.
Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.